PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
CRH plc (CRH)
114.271.68 (1.49%)
111.48 - 114.40
76.75 - 114.40
5.09M / 4.23M (Avg.)
23.96 | 4.77
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-6.75%
Negative revenue growth while CX stands at 69.27%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-71.54%
Negative gross profit growth while CX is at 71.00%. Joel Greenblatt would examine cost competitiveness or demand decline.
-93.45%
Negative EBIT growth while CX is at 70.69%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-93.45%
Negative operating income growth while CX is at 70.69%. Joel Greenblatt would press for urgent turnaround measures.
-7.86%
Negative net income growth while CX stands at 65.04%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
5.56%
EPS growth under 50% of CX's 65.22%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
5.56%
Diluted EPS growth under 50% of CX's 65.22%. Michael Burry would worry about an eroding competitive position or excessive dilution.
-11.52%
Share reduction while CX is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-11.51%
Reduced diluted shares while CX is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
277.81%
Positive 10Y revenue/share CAGR while CX is negative. John Neff might see a distinct advantage in product or market expansion over the competitor.
84.68%
5Y revenue/share CAGR at 50-75% of CX's 115.24%. Martin Whitman would worry about a lagging mid-term growth trajectory.
80.61%
3Y revenue/share CAGR similar to CX's 82.39%. Walter Schloss would assume both companies experience comparable short-term cycles.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
169.86%
Positive 10Y CAGR while CX is negative. John Neff might see a substantial advantage in bottom-line trajectory.
141.24%
5Y net income/share CAGR 1.25-1.5x CX's 115.79%. Bruce Berkowitz would check if a better product mix or cost discipline explains the gap.
184.47%
Below 50% of CX's 627.03%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
No Data
No Data available this quarter, please select a different quarter.
134.52%
5Y equity/share CAGR above 1.5x CX's 21.48%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
59.46%
3Y equity/share CAGR above 1.5x CX's 4.45%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.